Selected research
Industry Research
Fibromyalgia Antidepressant Industry Research Report 2026
Market perspective
The global Fibromyalgia Antidepressant market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Fibromyalgia Antidepressant is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Fibromyalgia Antidepressant is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Fibromyalgia Antidepressant is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Fibromyalgia Antidepressant include Pfizer, AbbVie, Virios Therapeutics, TONIX Pharmaceuticals Holdings, FSD Pharma and Aptinyx, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Fibromyalgia Antidepressant market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Fibromyalgia Antidepressant Market by Company
Pfizer
AbbVie
Virios Therapeutics
TONIX Pharmaceuticals Holdings
FSD Pharma
Aptinyx
Fibromyalgia Antidepressant Segment by Type
Milnacipran HCL
Venlafaxine
Duloxetine HCL
Others
Fibromyalgia Antidepressant Segment by Application
Retail Pharmacies
Online Sales
Drug stores
Hospital Pharmacies
Fibromyalgia Antidepressant Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibromyalgia Antidepressant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fibromyalgia Antidepressant and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibromyalgia Antidepressant.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Fibromyalgia Antidepressant manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Fibromyalgia Antidepressant by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Fibromyalgia Antidepressant in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Milnacipran HCL
- Venlafaxine
- Duloxetine HCL
- Others
Applications
- Retail Pharmacies
- Online Sales
- Drug stores
- Hospital Pharmacies
Companies covered
- Pfizer
- AbbVie
- Virios Therapeutics
- TONIX Pharmaceuticals Holdings
- FSD Pharma
- Aptinyx
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Fibromyalgia Antidepressant Market Size (2021-2032)
- 2.2.2 Global Fibromyalgia Antidepressant Sales (2021-2032)
- 2.2.3 Global Fibromyalgia Antidepressant Market Average Price (2021-2032)
- 2.3 Fibromyalgia Antidepressant by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Milnacipran HCL
- 2.3.3 Venlafaxine
- 2.3.4 Duloxetine HCL
- 2.3.5 Others
- 2.4 Fibromyalgia Antidepressant by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Sales
- 2.4.4 Drug stores
- 2.4.5 Hospital Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Fibromyalgia Antidepressant Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Fibromyalgia Antidepressant Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Fibromyalgia Antidepressant Revenue of Manufacturers (2021-2026)
- 3.4 Global Fibromyalgia Antidepressant Average Price by Manufacturers (2021-2026)
- 3.5 Global Fibromyalgia Antidepressant Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Fibromyalgia Antidepressant, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Fibromyalgia Antidepressant, Product Type & Application
- 3.8 Global Manufacturers of Fibromyalgia Antidepressant, Established Date
- 3.9 Global Fibromyalgia Antidepressant Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Pfizer
- 4.1.1 Pfizer Company Information
- 4.1.2 Pfizer Business Overview
- 4.1.3 Pfizer Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Pfizer Fibromyalgia Antidepressant Product Portfolio
- 4.1.5 Pfizer Recent Developments
- 4.2 AbbVie
- 4.2.1 AbbVie Company Information
- 4.2.2 AbbVie Business Overview
- 4.2.3 AbbVie Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 AbbVie Fibromyalgia Antidepressant Product Portfolio
- 4.2.5 AbbVie Recent Developments
- 4.3 Virios Therapeutics
- 4.3.1 Virios Therapeutics Company Information
- 4.3.2 Virios Therapeutics Business Overview
- 4.3.3 Virios Therapeutics Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Virios Therapeutics Fibromyalgia Antidepressant Product Portfolio
- 4.3.5 Virios Therapeutics Recent Developments
- 4.4 TONIX Pharmaceuticals Holdings
- 4.4.1 TONIX Pharmaceuticals Holdings Company Information
- 4.4.2 TONIX Pharmaceuticals Holdings Business Overview
- 4.4.3 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 TONIX Pharmaceuticals Holdings Fibromyalgia Antidepressant Product Portfolio
- 4.4.5 TONIX Pharmaceuticals Holdings Recent Developments
- 4.5 FSD Pharma
- 4.5.1 FSD Pharma Company Information
- 4.5.2 FSD Pharma Business Overview
- 4.5.3 FSD Pharma Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 FSD Pharma Fibromyalgia Antidepressant Product Portfolio
- 4.5.5 FSD Pharma Recent Developments
- 4.6 Aptinyx
- 4.6.1 Aptinyx Company Information
- 4.6.2 Aptinyx Business Overview
- 4.6.3 Aptinyx Fibromyalgia Antidepressant Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Aptinyx Fibromyalgia Antidepressant Product Portfolio
- 4.6.5 Aptinyx Recent Developments
5 Global Fibromyalgia Antidepressant Market Scenario by Region
- 5.1 Global Fibromyalgia Antidepressant Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Fibromyalgia Antidepressant Sales by Region: 2021-2032
- 5.2.1 Global Fibromyalgia Antidepressant Sales by Region: 2021-2026
- 5.2.2 Global Fibromyalgia Antidepressant Sales by Region: 2027-2032
- 5.3 Global Fibromyalgia Antidepressant Revenue by Region: 2021-2032
- 5.3.1 Global Fibromyalgia Antidepressant Revenue by Region: 2021-2026
- 5.3.2 Global Fibromyalgia Antidepressant Revenue by Region: 2027-2032
- 5.4 North America Fibromyalgia Antidepressant Market Facts & Figures by Country
- 5.4.1 North America Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Fibromyalgia Antidepressant Sales by Country (2021-2032)
- 5.4.3 North America Fibromyalgia Antidepressant Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Fibromyalgia Antidepressant Market Facts & Figures by Country
- 5.5.1 Europe Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Fibromyalgia Antidepressant Sales by Country (2021-2032)
- 5.5.3 Europe Fibromyalgia Antidepressant Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Fibromyalgia Antidepressant Market Facts & Figures by Country
- 5.6.1 Asia Pacific Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Fibromyalgia Antidepressant Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Fibromyalgia Antidepressant Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Fibromyalgia Antidepressant Market Facts & Figures by Country
- 5.7.1 South America Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Fibromyalgia Antidepressant Sales by Country (2021-2032)
- 5.7.3 South America Fibromyalgia Antidepressant Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Fibromyalgia Antidepressant Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Fibromyalgia Antidepressant Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Fibromyalgia Antidepressant Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Fibromyalgia Antidepressant Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Fibromyalgia Antidepressant Sales by Type (2021-2032)
- 6.1.1 Global Fibromyalgia Antidepressant Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Fibromyalgia Antidepressant Sales Market Share by Type (2021-2032)
- 6.2 Global Fibromyalgia Antidepressant Revenue by Type (2021-2032)
- 6.2.1 Global Fibromyalgia Antidepressant Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Fibromyalgia Antidepressant Revenue Market Share by Type (2021-2032)
- 6.3 Global Fibromyalgia Antidepressant Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Fibromyalgia Antidepressant Sales by Application (2021-2032)
- 7.1.1 Global Fibromyalgia Antidepressant Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Fibromyalgia Antidepressant Sales Market Share by Application (2021-2032)
- 7.2 Global Fibromyalgia Antidepressant Revenue by Application (2021-2032)
- 7.2.1 Global Fibromyalgia Antidepressant Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Fibromyalgia Antidepressant Revenue Market Share by Application (2021-2032)
- 7.3 Global Fibromyalgia Antidepressant Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Fibromyalgia Antidepressant Value Chain Analysis
- 8.1.1 Fibromyalgia Antidepressant Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Fibromyalgia Antidepressant Production Mode & Process
- 8.2 Fibromyalgia Antidepressant Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Fibromyalgia Antidepressant Distributors
- 8.2.3 Fibromyalgia Antidepressant Customers
9 Global Fibromyalgia Antidepressant Analyzing Market Dynamics
- 9.1 Fibromyalgia Antidepressant Industry Trends
- 9.2 Fibromyalgia Antidepressant Industry Drivers
- 9.3 Fibromyalgia Antidepressant Industry Opportunities and Challenges
- 9.4 Fibromyalgia Antidepressant Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst